0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > TrkB

TrkB

Brief Information

Name:Neurotrophic tyrosine kinase receptor type 2
Target Synonym:EC:2.7.10.1,Tropomyosin-related kinase B,Trk-B,GP145-TrkB,NTRK2,Neurotrophic Tyrosine Kinase Receptor Type 2,TRKB,BDNF-Tropomyosine Receptor Kinase B,BDNF/NT-3 Growth Factors Receptor,Tyrosine Kinase Receptor B,TrkB Tyrosine Kinase,EC 2.7.10.1,OBHD,Receptor, trkB,Neurotrophic Receptor Tyrosine Kinase 2,Neurotrophic Tyrosine Kinase, Receptor, Type 2,EIEE58,EC 2.7.10
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

Product ListCompare or Buy

Por estado del producto :
Por categoría de producto :
Por especies :
Por Conjugado::
Cat. No. Especies Descripción del producto Estructura Pureza Característica
CHEK-ATP082 Human HEK293/Human TrkB Stable Cell Line
NT2-H5228 Human Human TrkB / NTRK2 Protein, His Tag
NT2-H5228-structure
NT2-H5228-sds
NT2-H5254 Human Human TrkB / NTRK2 Protein, Fc Tag
NT2-H5254-structure
NT2-H5254-sds
ACRO Quality

Part of Bioactivity data

NT2-H5254-ELISA
 TrkB ELISA

Immobilized Human BDNF, premium grade (Cat. No. BDF-H5219) at 2 μg/mL (100 μL/well) can bind Human TrkB, Fc Tag (Cat. No. NT2-H5254) with a linear range of 1-20 ng/mL (Routinely tested).

NT2-H5228-ELISA
 TrkB ELISA

Immobilized Human BDNF, premium grade (Cat. No. BDF-H5219) at 1 μg/mL (100 μL/well) can bind Human TrkB, His Tag (Cat. No. NT2-H5228) with a linear range of 2-78 ng/mL (Routinely tested).

Synonym Name

NTRK2,TRKB,GP145-TrkB

Background

Neurotrophic tyrosine kinase receptor type 2 (NTRK2) is also known as BDNF/NT-3 growth factors receptor, Tropomyosin-related kinase B (TRKB) and TrkB tyrosine kinase, which belongs to the protein kinase superfamily or Tyr protein kinase family. Insulin receptor subfamily. NTRK2 / TrkB contains two Ig-like C2-type (immunoglobulin-like) domains, two LRR (leucine-rich) repeats, one LRRCT domain, one LRRNT domain, one protein kinase domain. NTRK2 / Trk-B is expressed in the central and peripheral nervous system. The catalytic activity of NTRK2 is ¡°ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate¡±. NTRK2 / TrkB involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx United States Carcinoma, Neuroendocrine; Thyroid Neoplasms Exelixis Inc 2012-11-29 Carcinoma, Adenosquamous; Uterine Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Gliosarcoma; Bile Duct Neoplasms; Peritoneal Neoplasms; Astrocytoma; Colorectal Neoplasms; Brain Neoplasms; Endometrial Neoplasms; Osteosarcoma; Urethral Neoplasms; Adenocarcinoma, Clear Cell; Neuroblastoma; Neurofibroma, Plexiform; Cholangiocarcinoma; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Breast Neoplasms; Carcinoma, Endometrioid; Neoplasms, Germ Cell and Embryonal; Meningioma; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Cancer, Papillary; Neoplasm Metastasis; Paraganglioma; Carcinoma, Hepatocellular; Sarcoma, Clear Cell; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Brain metastases; Lymphoma; Leukemia, Myeloid, Acute; Sarcoma, Alveolar Soft Part; Glioma; Carcinoma, Squamous Cell; Pain; Adrenal Cortex Neoplasms; Pancreatic neuroendocrine tumors (pNET); Glioblastoma; Kidney Diseases; Hepatoblastoma; Pheochromocytoma; Carcinoma, Renal Cell; Rejection of liver transplantation; Carcinoid Details
Entrectinib NMS-E628; RXDX-101; RG-6268 Approved Nerviano Medical Sciences Srl 罗圣全, Rozlytrek Japan Carcinoma, Non-Small-Cell Lung Chugai Pharmaceutical Co Ltd 2019-06-18 Sarcoma; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Glioma; Hepatic Insufficiency; Colorectal Neoplasms; Lymphoproliferative Disorders; Breast Neoplasms; Cholangiocarcinoma; Solid tumours; Brain Neoplasms; Neuroendocrine Tumors; Central Nervous System Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Ovarian Neoplasms; Skin Melanoma; Hematologic Neoplasms Details
Larotrectinib sulfate LOXO-101; ARRY-470; BAY-2757556 Approved Array Biopharma Vitrakvi, 维泰凯 United States Solid tumours Bayer Healthcare Pharmaceuticals Inc 2018-11-26 Glioma; Neuroblastoma; Sarcoma; Sarcoma, Ewing; Osteosarcoma; Histiocytosis, Langerhans-Cell; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Histiocytic Sarcoma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Multiple Myeloma; Uterine Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Lymphoma; Esophageal adenocarcinoma; Neoplasms, Neuroepithelial; Thyroid Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Xanthogranuloma, Juvenile; Uterine Cervical Neoplasms; Melanoma; Stomach Neoplasms; Solid tumours; Leukemia; Ependymoma; Medulloblastoma; Rhabdomyosarcoma; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Fibrosarcoma; Esophageal Neoplasms; Rectal Neoplasms; Wilms Tumor; Skin Neoplasms; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neo Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Lymphoma, Mantle-Cell; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
BrAD-R13 BrAD-R13; BrADR13 Phase 1 Clinical Shanghai Braegen Pharmaceutical Co Ltd Alzheimer Disease Details
ACD-856 ACD-856 Phase 1 Clinical Alzecure Pharma Ab Alzheimer Disease; Cognition Disorders Details
FB-1001 FB_-1001; FB-1001; FB1001 Phase 1 Clinical 4b Technologies (Suzhou) Ltd Optic Nerve Diseases; Glaucoma Details
Lestaurtinib SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 Phase 3 Clinical Kyowa Hakko Kirin Co Ltd Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neuroblastoma; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje